One of our clients published preclinical data on NASH-fibrosis on Liver Cancer
We announced that a study in the STAM™ mouse model of NASH performed by SMC Laboratories Inc. has been published in Liver Cancer by Kurume University:
Title: “Effects of a DPP4 inhibitor on progression of NASH-related HCC and the p62/Keap1/Nrf2-Pentose phosphate pathway in a mouse model”
The results of the study demonstrated in the STAM™ model that Sitagliptin (DDP4 inhibitor) prevented the progression of NASH-related HCC and DDP4i downregulated the pentose phosphate pathway with suppression of the p62/Keap1/ Nrf2 pathway.